Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced it has entered into an exclusive license agreement with Pint Pharma for the commercialization of Beleodaq® (belinostat), Onxeo’s pan-HDAC inhibitor for PTCL (peripheral T-cell lymphoma), in key South American countries.

NEWTOWN, Pa., March 05, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS),

Pharmacovigilance

If you or a person you know experiences any discomfort or adverse effect that may, or may not, have been caused by treatment with a Pint Pharma product, you can report it to us. Communication with our patients and health professionals who prescribe our medicines is very important to us.

To find the e-mail address for your country, click here.

Pint Pharma has its own pharmacovigilance system that monitors the safety and efficacy of our products when our patients are using them.

Si Ud. o una persona que conoce experimenta alguna molestia o efecto adverso que puede, o no, haber sido causado por el tratamiento con un producto Pint Pharma, puede informarnos lo sucedido. Es muy importante para nosotros la comunicación con nuestros pacientes y profesionales de la salud que prescriben nuestros medicamentos.

Para encontrar la dirección de correo electrónico correspondiente a su país, haga clic aquí.

Pint Pharma cuenta con su propio sistema de farmacovigilancia que monitorea la seguridad y eficacia de nuestros productos cuando nuestros pacientes los están usando.